Comparing Organogenesis (ORGO) and Its Rivals

Organogenesis (NASDAQ:ORGO) is one of 844 publicly-traded companies in the “Biotechnology” industry, but how does it compare to its competitors? We will compare Organogenesis to similar companies based on the strength of its risk, profitability, valuation, dividends, institutional ownership, earnings and analyst recommendations.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Organogenesis and its competitors, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organogenesis	1	2	0	0	1.67
Organogenesis Competitors	9873	15288	45637	1598	2.54

Organogenesis currently has a consensus price target of $4.33, suggesting a potential upside of 384.17%. As a group, “Biotechnology” companies have a potential upside of 127.36%. Given Organogenesis’ higher possible upside, analysts clearly believe Organogenesis is more favorable than its competitors.

Profitability

This table compares Organogenesis and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Organogenesis	-39.34%	-55.28%	-23.72%
Organogenesis Competitors	-12,323.33%	-195.91%	-30.60%

Institutional and Insider Ownership

49.6% of Organogenesis shares are held by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are held by institutional investors. 18.8% of Organogenesis shares are held by company insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Organogenesis and its competitors gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Organogenesis	$564.17 million	$37.03 million	-0.73
Organogenesis Competitors	$702.34 million	$9.48 million	-18.80

Organogenesis’ competitors have higher revenue, but lower earnings than Organogenesis. Organogenesis is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Volatility and Risk

Organogenesis has a beta of 1.48, suggesting that its stock price is 48% more volatile than the S&P 500. Comparatively, Organogenesis’ competitors have a beta of -1.84, suggesting that their average stock price is 284% less volatile than the S&P 500.

Summary

Organogenesis beats its competitors on 9 of the 13 factors compared.

Organogenesis Company Profile

Organogenesis Holdings Inc. is a regenerative medicine company that develops, manufactures and commercializes products for advanced wound care and surgical and sports medicine. The company’s products are designed to support tissue repair and healing in a range of clinical settings. Its portfolio includes wound-care products such as Apligraf, a bioengineered skin substitute, and products made from or incorporating materials including placental tissue and purified collagen. Organogenesis also offers products for surgical and sports medicine applications.